Intermittent chemotherapy in metastatic androgen-independent prostate cancer

Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA...

Descripción completa

Detalles Bibliográficos
Autores principales: Beer, T M, Garzotto, M, Henner, W D, Eilers, K M, Wersinger, E M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376967/
https://www.ncbi.nlm.nih.gov/pubmed/12966410
http://dx.doi.org/10.1038/sj.bjc.6601232
_version_ 1782154762462953472
author Beer, T M
Garzotto, M
Henner, W D
Eilers, K M
Wersinger, E M
author_facet Beer, T M
Garzotto, M
Henner, W D
Eilers, K M
Wersinger, E M
author_sort Beer, T M
collection PubMed
description Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml(−1). Chemotherapy was suspended until a rise in PSA⩾50% and 1 ng ml(−1). The median duration of treatment holiday was 20 weeks (13–43+weeks) and all patients retained sensitivity to re-treatment. Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.
format Text
id pubmed-2376967
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23769672009-09-10 Intermittent chemotherapy in metastatic androgen-independent prostate cancer Beer, T M Garzotto, M Henner, W D Eilers, K M Wersinger, E M Br J Cancer Clinical Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml(−1). Chemotherapy was suspended until a rise in PSA⩾50% and 1 ng ml(−1). The median duration of treatment holiday was 20 weeks (13–43+weeks) and all patients retained sensitivity to re-treatment. Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study. Nature Publishing Group 2003-09-15 2003-09-09 /pmc/articles/PMC2376967/ /pubmed/12966410 http://dx.doi.org/10.1038/sj.bjc.6601232 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Beer, T M
Garzotto, M
Henner, W D
Eilers, K M
Wersinger, E M
Intermittent chemotherapy in metastatic androgen-independent prostate cancer
title Intermittent chemotherapy in metastatic androgen-independent prostate cancer
title_full Intermittent chemotherapy in metastatic androgen-independent prostate cancer
title_fullStr Intermittent chemotherapy in metastatic androgen-independent prostate cancer
title_full_unstemmed Intermittent chemotherapy in metastatic androgen-independent prostate cancer
title_short Intermittent chemotherapy in metastatic androgen-independent prostate cancer
title_sort intermittent chemotherapy in metastatic androgen-independent prostate cancer
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376967/
https://www.ncbi.nlm.nih.gov/pubmed/12966410
http://dx.doi.org/10.1038/sj.bjc.6601232
work_keys_str_mv AT beertm intermittentchemotherapyinmetastaticandrogenindependentprostatecancer
AT garzottom intermittentchemotherapyinmetastaticandrogenindependentprostatecancer
AT hennerwd intermittentchemotherapyinmetastaticandrogenindependentprostatecancer
AT eilerskm intermittentchemotherapyinmetastaticandrogenindependentprostatecancer
AT wersingerem intermittentchemotherapyinmetastaticandrogenindependentprostatecancer

Ejemplares similares